76596-57-1 Usage
Uses
Used in Pharmaceutical Industry:
3-bromo-alpha-[[(1,1-dimethylethyl)amino]methyl]isoxazole-5-methanol is used as an active pharmaceutical ingredient (API) for its potential therapeutic effects. 3-bromo-alpha-[[(1,1-dimethylethyl)amino]methyl]isoxazole-5-methanol's unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs to treat various medical conditions.
Used in Chemical Research:
In the field of chemical research, 3-bromo-alpha-[[(1,1-dimethylethyl)amino]methyl]isoxazole-5-methanol serves as a valuable starting material for the synthesis of other complex organic molecules. Its versatile structure can be further modified to create new compounds with different properties and applications.
Used in Material Science:
3-bromo-alpha-[[(1,1-dimethylethyl)amino]methyl]isoxazole-5-methanol can be utilized in the development of novel materials with specific properties. Its unique molecular structure may contribute to the creation of materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity.
For example, the result for Broxaterol is:
Uses
Used in Respiratory Medicine:
Broxaterol is used as a bronchodilator for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its ability to activate β2-adrenergic receptors leads to the relaxation of smooth muscle in the airways, reducing inflammation and constriction. This results in improved airflow and relief from respiratory symptoms.
Used in Sports Medicine:
Due to its bronchodilating effects, Broxaterol may also be used in sports medicine to enhance athletic performance, particularly in endurance sports where efficient oxygenation of the muscles is crucial. However, it is essential to note that the use of such substances in sports may be subject to regulations and restrictions by various sports governing bodies.
Check Digit Verification of cas no
The CAS Registry Mumber 76596-57-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,5,9 and 6 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 76596-57:
(7*7)+(6*6)+(5*5)+(4*9)+(3*6)+(2*5)+(1*7)=181
181 % 10 = 1
So 76596-57-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H15BrN2O2/c1-9(2,3)11-5-6(13)7-4-8(10)12-14-7/h4,6,11,13H,5H2,1-3H3
76596-57-1Relevant academic research and scientific papers
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.
Chemoenzymatic Synthesis of Chiral Isoxazole Derivatives
Amici, Marco De,Micheli, Carlo De,Carrea, Giacomo,Spezia, Sandro
, p. 2646 - 2650 (2007/10/02)
The synthesis of the two enantiomers of 1-(3-bromo-5-isoxazolyl)-2-(tert-butylamino)ethanol (1), a potent and selective β2-adrenergic stimulant, has been efficiently accomplished by enzyme-catalyzed transformations.The absolute configurations are attributed to (+)- and (-)-1 by correlation with (S)-3-butyn-2-ol.The S enantiomer was prepared in >98percent enantiomeric excess by reducing α-bromo ketone 4 in the presence of alcohol dehydrogenase from Thermoanaerobium brockii and the R enantiomer was obtained in 97percent ee through a kinetic resolution of the racemic bromohydrin(+/-)-5, in organic solvents, catalyzed by lipase P from Pseudomonas fluorescens.The experimental conditions for the lipase-catalyzed asymmetric transesterifications were optimized in order to improve reaction rates and the enantiomeric excess of the products.
